Arcato Labs is Jay’s Fourth Entrepreneurial New Venture
DURHAM, N.C., March 15, 2016 – Dr. Michael Jay, the Fred Eshelman Distinguished Professor of Molecular Pharmaceutics, is the 2016 recipient of the Distinguished Teaching Award for Postbaccalaureate Instruction from the University of North Carolina at Chapel Hill.
Jay was selected for the award based on his dedication to his students and the University of North Carolina at Chapel Hill community.
“Both your students and faculty colleagues were enthusiastic in their praise of your commitment to the highest standard of teaching,” said Chancellor Carol L. Folt in a letter notifying Jay of his award. “You clearly provided your students with a rich, supportive environment for higher learning and an exceptionally positive role model for their own careers.”
Dr. Jay’s research projects are centered on the interface between the pharmaceutical and nuclear sciences, involving the application of pharmaceutical approaches to solve problems related to nuclear imaging and therapy, and the use of radioanalytical approaches to solve problems encountered in the development of novel formulations and drug delivery systems.
Dr. Jay is the Founder of Arcato and has been awarded patents for Arcato’s drug delivery and formulations.
Dr. Jay joined the UNC Eshelman School of Pharmacy in 2008 after a 27-year career at the University of Kentucky College of Pharmacy. In 2014, Dr. Jay was named the University of Kentucky Outstanding Graduate Program Alumnus for the Pharmaceutical Sciences.
About Arcato Laboratories
Arcato’s first product, a medical device named OraWax™, targets orthodontists and their patients as the first effective treatment for oral discomfort caused by orthodontic appliances (braces). Arcato is raising a $1 million Series B financing to complete final regulatory approval for OraWax™ and launch this product in the United States. For more information on investing, please visit our Investor Relations Page, or contact our Investment Advisor, Thomas E. Vass, at (919) 975-4856 with any questions about our investment process.